MX2024006743A - Unidad de union a antigeno ccr8 y usos de los mismos. - Google Patents

Unidad de union a antigeno ccr8 y usos de los mismos.

Info

Publication number
MX2024006743A
MX2024006743A MX2024006743A MX2024006743A MX2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A
Authority
MX
Mexico
Prior art keywords
ccr8
antigen binding
binding unit
antibody
cancer
Prior art date
Application number
MX2024006743A
Other languages
English (en)
Spanish (es)
Inventor
David Bellovin
Jing Zhang
Min Chen
Xinchuan Dai
Shou Li
Bing Wan
Hongshui Liu
Lishan Kang
Lina Wang
Shang Yin
Wenhua Shi
Original Assignee
Zai Lab Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zai Lab Shanghai Co Ltd filed Critical Zai Lab Shanghai Co Ltd
Publication of MX2024006743A publication Critical patent/MX2024006743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024006743A 2021-12-02 2022-12-02 Unidad de union a antigeno ccr8 y usos de los mismos. MX2024006743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021134930 2021-12-02
PCT/CN2022/136276 WO2023098888A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Publications (1)

Publication Number Publication Date
MX2024006743A true MX2024006743A (es) 2024-08-27

Family

ID=86611552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006743A MX2024006743A (es) 2021-12-02 2022-12-02 Unidad de union a antigeno ccr8 y usos de los mismos.

Country Status (11)

Country Link
US (1) US20250034266A1 (cg-RX-API-DMAC7.html)
EP (1) EP4441098A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541680A (cg-RX-API-DMAC7.html)
KR (1) KR20240112929A (cg-RX-API-DMAC7.html)
CN (1) CN119072494A (cg-RX-API-DMAC7.html)
AU (1) AU2022400921A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239784A1 (cg-RX-API-DMAC7.html)
IL (1) IL313177A (cg-RX-API-DMAC7.html)
MX (1) MX2024006743A (cg-RX-API-DMAC7.html)
TW (1) TW202342533A (cg-RX-API-DMAC7.html)
WO (1) WO2023098888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
TW202511293A (zh) * 2023-05-23 2025-03-16 中國大陸商再鼎醫藥(上海)有限公司 包含抗ccr8抗體的製劑及其用途
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN120230205A (zh) * 2023-12-29 2025-07-01 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
US20250034266A1 (en) 2025-01-30
EP4441098A1 (en) 2024-10-09
WO2023098888A1 (en) 2023-06-08
TW202342533A (zh) 2023-11-01
CA3239784A1 (en) 2023-06-08
IL313177A (en) 2024-07-01
JP2024541680A (ja) 2024-11-08
AU2022400921A1 (en) 2024-06-27
EP4441098A4 (en) 2026-03-04
KR20240112929A (ko) 2024-07-19
CN119072494A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
JOP20210289A1 (ar) مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
EA202190535A1 (ru) Бифункциональное антитело против pd-1 и против vegfa, его фармацевтическая композиция и его применение
MX2022015374A (es) Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso.
MY208638A (en) Anti-steap1 antigen-binding protein
MY207205A (en) Cd3 antibody and pharmaceutical use thereof
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
MX2022016254A (es) Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr.
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
MX2024015391A (es) Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
SA520420225B1 (ar) cMET مترافقات عقار من عوامل رابطة أحادية النسيلة من واستخداماتها
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
CL2025002617A1 (es) Conjugados anticuerpo-fármaco administrados por vía subcutánea para el uso en el tratamiento del cáncer
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
CL2025001502A1 (es) Conjugados anticuerpo-fármaco anti-cea y métodos de uso
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.